This Article Full Text Full Text (PDF) All Versions of this Article: 45/2/294    most recent 01.HYP.0000151361.31736.96v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, H. Articles by Weinberger, M. H. Search for Related Content PubMed PubMed Citation Articles by Ho, H. Articles by Weinberger, M. H. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections Other hypertension

(Hypertension. 2005;45:294.)
© 2005 American Heart Association, Inc.

Scientific Contributions

Association Between the CYP3A5 Genotype and Blood Pressure

Herbert Ho; Amar Pinto; Stephen D. Hall; David A. Flockhart; Lang Li; Todd C. Skaar; Peter Cadman; Daniel T. O’Connor; Urban Wagner; Naomi S. Fineberg; Myron H. Weinberger

From the Divisions of Clinical Pharmacology (H.H., A.P., S.D.H., D.A.F., T.C.S.), Biostatistics (L.L., N.S.F.), and Endocrinology and Metabolism (U.W., M.H.W.), Department of Medicine, Indiana University School of Medicine, Indianapolis; and Division of Nephrology (P.C., D.T.O.), Department of Medicine, University of California San Diego School of Medicine.

Correspondence to Herbert Ho, MD, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 W Tenth St, WD Myers Room W7123, Indianapolis, IN 46202. E-mail heho{at}iupui.edu

We tested the hypothesis that the presence of a CYP3A5*1 allele is associated with increases in blood pressure in 2 studies of subjects with a total of 683 participants. The first study involving 271 subjects was part of a longitudinal study conducted at Indiana University Medical Center that consisted of 2 phases. The first phase studied the relationship of salt sensitivity with blood pressure, whereas the second phase, conducted 26 years later, studied the relationship between blood pressure, carbohydrate intolerance, and vascular compliance in the same subjects. The second study was a cross-sectional evaluation of 412 normotensive and hypertensive subjects conducted at the University of California San Diego. The second study (Mantel–Haenszel ² test; P=0.05) showed that a greater proportion of black participants with poor blood pressure control had CYP3A5*1/*1 genotype. Evaluation of the untreated blood pressure from phase 1 of the first study showed that the blacks with CYP3A5*3/*3 (146±35 mm Hg) had a higher systolic blood pressure than those with the *1/*3 (119±14.1 mm Hg; P=0.0006) and *1/*1 (125±17.4 mm Hg; P=0.009) genotypes. For blacks in study 2, the CYP3A5*1 allele was more common in hypertensives (Fisher exact test; P=0.025) than normotensives. In whites there was no association between CYP3A5 genotype and blood pressure in either study. We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.

Key Words: cytochrome p450 • blood pressure • genetics • polymorphism

This article has been cited by other articles:

				M. Canonico, E. Bouaziz, L. Carcaillon, C. Verstuyft, A. Guiochon-Mantel, L. Becquemont, P.-Y. Scarabin, and for the Estrogen Thromboembolism Risk (ESTHER) Stu Synergism between Oral Estrogen Therapy and Cytochrome P450 3A5*1 Allele on the Risk of Venous Thromboembolism among Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3082 - 3087. [Abstract] [Full Text] [PDF]

				D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, June 24, 2008; 117(25): e510 - e526. [Abstract] [Full Text] [PDF]

				D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension, June 1, 2008; 51(6): 1403 - 1419. [Abstract] [Full Text] [PDF]

				M. Yazdanpanah, Y. S. Aulchenko, A. Hofman, J. A.M.J.L. Janssen, F. A. Sayed-Tabatabaei, R. H.N. van Schaik, O. H. Klungel, B. H.C.H. Stricker, H. A.P. Pols, J. C.M. Witteman, et al. Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes Diabetes, July 1, 2007; 56(7): 1905 - 1912. [Abstract] [Full Text] [PDF]

				F.H. Messerli, G. Mancia, C.R. Conti, A.C. Hewkin, S. Kupfer, A. Champion, R. Kolloch, A. Benetos, C.J. Pepine, K. Nakagawa, et al. Lowering of Blood Pressure--The Lower, the Better?: Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? Ann Intern Med 144: 884-893, 2006 J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2345 - 2352. [Full Text] [PDF]